[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![AlfredoM617 Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::47191740.png) Alfredo M [@AlfredoM617](/creator/twitter/AlfredoM617) on x XXX followers
Created: 2025-07-14 19:36:05 UTC

Safety and Tolerability $VKTX

VK2735 stands out for low incidence of severe gastrointestinal side effects, the Achilles’ heel of most GLP-1 agonists. Across trials:

Nausea was common but mild in over two-thirds of cases

No severe vomiting with oral or injectable

Low discontinuation rates (~13%, on par with placebo)

If these tolerability benefits hold in Phase 3, VK2735 could become the first widely acceptable GLP-1-based therapy for patients who’ve struggled with side effects from Wegovy or Mounjaro.


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1944843360016928916/c:line.svg)

**Related Topics**
[par](/topic/par)
[rates](/topic/rates)
[$vktx](/topic/$vktx)

[Post Link](https://x.com/AlfredoM617/status/1944843360016928916)